The selectivity of inhibitors of protein kinase CK2: an update

被引:209
作者
Pagano, Mario A. [2 ,3 ,4 ]
Bain, Jenny [5 ,6 ]
Kazimierczuk, Zygmunt [1 ]
Sarno, Stefania [2 ,3 ,4 ]
Ruzzene, Maria [2 ,3 ,4 ]
Di Maira, Giovanni [2 ,3 ,4 ]
Elliott, Matthew [5 ,6 ]
Orzeszko, Andrzej [7 ]
Cozza, Giorgio [2 ,3 ]
Meggio, Flavio [2 ,3 ]
Pinna, Lorenzo A. [2 ,3 ,4 ]
机构
[1] Polish Acad Sci, Med Res Ctr, Lab Expt Pharmacol, PL-02106 Warsaw, Poland
[2] Univ Padua, Dept Biol Chem, I-35131 Padua, Italy
[3] Univ Padua, Inst Neurosci, CNR, I-35131 Padua, Italy
[4] VIMM, I-35129 Padua, Italy
[5] Univ Dundee, Prot Phosphorylat Unit, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland
[6] Univ Dundee, Prot Phosphorylat Unit, MRC, Dundee DD1 5EH, Scotland
[7] Mil Univ Technol, PL-00908 Warsaw, Poland
基金
英国医学研究理事会;
关键词
ATP mimetics; casein kinase 2 (CK2) inhibitor; drug design; homeodomain-interacting protein kinase 2 (HIPK2); provirus integration site for Moloney murine leukaemia virus 1 (PIM 1); selectivity;
D O I
10.1042/BJ20080309
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CK2 (casein kinase 2) is a very pleiotropic serine/threonine protein kinase whose abnormally high constitutive activity has often been correlated to pathological conditions with special reference to neoplasia. The two most widely used cell permeable CK2 inhibitors, TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole), are marketed as quite specific CK2 blockers. In the present study we show, by using a panel of approx. 80 protein kinases, that DMAT and its parent compound TBI (or TBBz; 4,5,6,7-tetrabronio-1H-benzimidazole) are potent inhibitors of several other kinases, with special reference to PIM (provirus integration site for Moloney murine leukaemia virus)1, PIM2, PIM3, PKD1 (protein kinase D1), HIPK2 (homeodomain-interacting protein kinase 2) and DYRK 1a (dual-specificity tyrosine-phosphorylated and -regulated kinase 1a). In contrast, TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3. In an attempt to
引用
收藏
页码:353 / 365
页数:13
相关论文
共 50 条
[11]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[12]   Identification of ellagic acid as potent inhibitor of protein kinase CK2: A successful example of a virtual screening application [J].
Cozza, G ;
Bonvini, P ;
Zorzi, E ;
Poletto, G ;
Pagano, MA ;
Sarno, S ;
Donella-Deana, A ;
Zagotto, G ;
Rosolen, A ;
Pinna, LA ;
Meggio, F ;
Moro, S .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (08) :2363-2366
[13]   Novel synthesis of indazoles from (η6-arene)tricarbonylchromium complexes [J].
da Costa, MRG ;
Curto, MJM ;
Davies, SG ;
Duarte, MT ;
Resende, C ;
Teixeira, FC .
JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2000, 604 (02) :157-169
[14]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[15]  
DAYAMAKIN M, 1994, CANCER RES, V54, P2262
[16]   Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis [J].
Di Stefano, V ;
Rinaldo, C ;
Sacchi, A ;
Soddu, S ;
D'Orazi, G .
EXPERIMENTAL CELL RESEARCH, 2004, 293 (02) :311-320
[17]  
Druker BJ, 2005, HANDB EXP PHARMACOL, V167, P391
[18]   An unbiased evaluation of CK2 inhibitors by chemoproteomics [J].
Duncan, James S. ;
Gyenis, Laszlo ;
Lenehan, John ;
Bretner, Maria ;
Graves, Lee M. ;
Haystead, Timothy A. ;
Litchfield, David W. .
MOLECULAR & CELLULAR PROTEOMICS, 2008, 7 (06) :1077-1088
[19]   Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2 [J].
Duncan, James S. ;
Litchfield, David W. .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2008, 1784 (01) :33-47
[20]  
Faust RA, 2000, HEAD NECK-J SCI SPEC, V22, P341, DOI 10.1002/1097-0347(200007)22:4<341::AID-HED5>3.0.CO